- Study protocol
- Open Access
The PRO-ACTIVE trial protocol: a randomized study comparing the effectiveness of PROphylACTic swallow InterVEntion for patients receiving radiotherapy for head and neck cancer
BMC Cancer volume 21, Article number: 1100 (2021)
Swallowing therapy is commonly provided as a treatment to lessen the risk or severity of dysphagia secondary to radiotherapy (RT) for head and neck cancer (HNC); however, best practice is not yet established. This trial will compare the effectiveness of prophylactic (high and low intensity) versus reactive interventions for swallowing in patients with HNC undergoing RT.
This multi-site, international randomized clinical trial (RCT) will include 952 adult patients receiving radiotherapy for HNC and who are at high risk for post-RT dysphagia. Participants will be randomized to receive one of three interventions for swallowing during RT: RE-ACTIVE, started promptly if/when dysphagia is identified; PRO-ACTIVE EAT, low intensity prophylactic intervention started before RT commences; or, PRO-ACTIVE EAT+EXERCISE, high intensity prophylactic intervention also started before RT commences. We hypothesize that the PRO-ACTIVE therapies are more effective than late RE-ACTIVE therapy; and, that the more intensive PRO-ACTIVE (EAT + EXERCISE) is superior to the low intensive PRO-ACTIVE (EAT). The primary endpoint of effectiveness is duration of feeding tube dependency one year post radiation therapy, selected as a pragmatic outcome valued equally by diverse stakeholders (e.g., patients, caregivers and clinicians). Secondary outcomes will include objective measures of swallow physiology and function, pneumonia and weight loss, along with various patient-reported swallowing-related outcomes, such as quality of life, symptom burden, and self-efficacy.
Dysphagia is a common and potentially life-threatening chronic toxicity of radiotherapy, and a priority issue for HNC survivors. Yet, the optimal timing and intensity of swallowing therapy provided by a speech-language pathologist is not known. With no clearly preferred strategy, current practice is fraught with substantial variation. The pragmatic PRO-ACTIVE trial aims to specifically address the decisional dilemma of when swallowing therapy should begin (i.e., before or after a swallowing problem develops). The critical impact of this dilemma is heightened by the growing number of young HNC patients in healthcare systems that need to allocate resources most effectively. The results of the PRO-ACTIVE trial will address the global uncertainty regarding best practice for dysphagia management in HNC patients receiving radiotherapy.
The protocol is registered with the US Patient Centered Outcomes Research Institute, and the PRO-ACTIVE trial was prospectively registered at ClinicalTrials.gov, under the identifier NCT03455608; First posted: Mar 6, 2018; Last verified: Jun 17, 2021.
Protocol Version: 1.3 (January 27, 2020).
Dysphagia is a priority issue in Head and Neck cancer (HNC) survivorship. Difficulty swallowing (dysphagia) is a common and potentially life-threatening chronic toxicity of radiotherapy (RT) for HNC. While an independent predictor of quality of life (QOL) in HNC survivorship, dysphagia can also have a devastating impact on the health of patients. The lifetime risk of aspiration pneumonia is 20–24% after chemoradiation for HNC [1, 2], representing a 2.7-fold elevated risk of pneumonia in HNC survivors (age ≥ 65 years) over matched non-cancer controls in the United States population. Aspiration pneumonia also confers a 42% excess risk of mortality among HNC survivors who develop pneumonia relative to those who do not . Moreover, dysphagia predisposes to malnutrition and nutritional deficiencies. Despite treatment advances, up to 70% require tube feeding, typically for a minimum of several months during and immediately following RT ; feeding tube dependency persists in approximately 45% of patients 3 months after finishing cancer treatment [4,5,6,7,8,9].
Despite improvements in conformal planning techniques to lessen normal tissue injury from RT , almost all patients experience some degree of early dysphagia. RT dose thresholds for dysphagia suggest that risk persists even with emerging investigational efforts in swallowing optimized RT planning . While acute dysphagia improves for the majority of patients in the early months after RT ends, many survivors suffer chronic or progressive radiation-associated dysphagia years after treatment. In fact, among those with late (beyond 5 years) toxicities, 66% have severe dysphagia requiring lifelong feeding tube dependence . Recent work highlights the severity of this endpoint to cancer survivors, who ranked feeding tube dependency as one of 6 outcomes of their cancer treatment that were worse than death .
There is a rapidly growing pool of HNC survivors at risk for chronic dysphagia, with 68,785 incident cases annually in the USA and Canada [14, 15]. A large proportion of HNCs are now human papillomavirus (HPV)-driven oropharyngeal cancers, the incidence of which is expected to sharply rise through 2030 . Almost all of this fast growing, large subgroup of HNC survivors have been treated with curative RT at doses ≥60 Gray, sufficient to induce chronic dysphagia. HPV-associated HNC is diagnosed younger (median age: 54 years)  than tobacco-related HNC with excellent five-year survival probability of 79% . As such, survivors have the potential to live many active years (even decades) with toxicities of RT including dysphagia.
Oncologists commonly refer patients for swallowing therapy with a speech language pathologist to lessen risk or severity of radiation-associated dysphagia, but best practice is not established using prospective evidence. Some patients are monitored and referred for dysphagia interventions only in response to a swallow problem (RE-ACTIVE therapy), a so-called “wait and see” approach. Thus, RE-ACTIVE therapy aims to reverse an already impaired swallow back to its functional pre-morbid state, typically with exercise and mealtime adjustment . In contrast, other patients are referred pre-emptively for prophylactic “PRO-ACTIVE” swallowing therapy that aims to prevent or lessen the severity or duration of dysphagia. PRO-ACTIVE interventions are prescribed early – before the swallow problem begins – in an effort to inhibit disuse atrophy and fibrosis . PRO-ACTIVE therapy can vary in intensity. Some receive PRO-ACTIVE therapy focused on keeping them eating to keep muscles active (our PRO-ACTIVE EAT group) , while others are also prescribed swallowing exercise between meals (our PRO-ACTIVE EAT+EXCERCISE group) . The two broad categories, PRO-ACTIVE versus RE-ACTIVE, as well as the variation in intensity of PRO-ACTIVE therapy (‘EAT versus ‘EAT+EXERCISE’), represent the most common therapy models in North America  and the UK .
The benefits of swallowing therapy in ideal settings, regardless of its timing and intensity, are suggested by many single institution observational and controlled efficacy trials. Two recent systematic reviews (one from the PRO-ACTIVE investigators) showed benefits to various outcomes, including feeding tube dependence, QOL, swallow efficiency, function, and swallow physiology from both PRO-ACTIVE (early) and RE-ACTIVE (delayed) therapy [21, 23]. Specifically, pooled data from efficacy trials suggested lower feeding tube dependence among those who received PRO-ACTIVE therapy with exercise relative to either RE-ACTIVE or lower intensity PRO-ACTIVE therapy (odds ratio [OR]: 0.53, 90% CI: 0.29, 0.97, 21). Likewise, our meta-analysis identified equally convincing benefit to swallow function from RE-ACTIVE therapy (OR: 3.70, 95% CI, 1.53, 8.94) compared to either no therapy or less intensive therapy . Unfortunately, no review to date has identified the timing (PRO-ACTIVE versus RE-ACTIVE) or intensity (less versus more) most effective when applied in a real-world setting. Despite several meritorious efforts using small efficacy trials and even more robust meta-analysis, the decisional dilemma regarding what is the best timing and intensity of behavioural swallowing interventions during RT remains, precluding evidence-based prescription and effective health system resource allocation.
The chief dilemma for therapy providers centers on when swallowing therapy should begin. The investigators’ survey  of North American speech language pathologists reported an even distribution among these therapies, with 48% of respondents practicing PRO-ACTIVE therapy versus 52% who used RE-ACTIVE therapy. Clearly clinical equipoise exists and contributes to variation in our practice. The dilemma is further heightened considering the target population comprises rapidly growing numbers of younger HNC survivors who face considerable competing toxicities during RT, of which dysphagia registers the among the most impactful . This growing prevalence of HNC survivors with dysphagia makes it even more imperative to identify the most effective therapies, so that healthcare systems can allocate limited resources to optimize functional recovery after curative oncologic treatment.
Aims and hypotheses
To address this evidence gap, the primary aim (Aim 1) of the PRO-ACTIVE trial is to compare the effectiveness of PRO-ACTIVE versus RE-ACTIVE swallowing interventions among patients with HNC planned to undergo RT. We hypothesize that at 12-months post radiotherapy the combined PRO-ACTIVE therapies are more effective than RE-ACTIVE therapy (Hyp 1.1); and, if so, that more intensive PRO-ACTIVE (EAT + EXERCISE) is superior to less intensive PRO-ACTIVE (EAT) (Hyp 1.2). Effectiveness will be measured based on reduced duration of feeding tube dependency, a pragmatic outcome valued by diverse stakeholders including patients, caregivers and clinicians [13, 21, 25, 26].
The second aim (Aim 2) of the PRO-ACTIVE trial is to compare the relative benefit or harm of PRO-ACTIVE to RE-ACTIVE swallowing intervention on all secondary outcomes at both 3- and 12- months post radiotherapy, namely: swallowing impairment, maximum interincisal opening (trismus), swallowing-related QOL, symptom burden, self-reported pneumonia, malnutrition and mood disorder, cancer coping strategies, diet level, feeding tube rates, weight loss, hospitalization and/or emergency department (ED) presentation. In addition, the second aim will compare the benefit on reduced duration of feeding tube presence at 3-month post radiotherapy. Our hypothesis for this second aim is that the combined PRO-ACTIVE interventions will result in better secondary outcomes at 3- and 12- months following the completion of RT (Hyp 2.1). As in our primary aim, for each secondary outcome for which PRO-ACTIVE is superior, dose response of the PRO-ACTIVE arms will be examined hypothesizing the more intensive therapy as superior (Hyp 2.2).
The third aim (Aim 3) of the PRO-ACTIVE trial is to explore the relative benefit or harm of the PRO-ACTIVE and RE-ACTIVE swallowing interventions in relevant subgroups according to the following: age, tumor site, prior surgery, radiation dose, chemotherapy use, and prophylactic feeding tube use. Our hypothesis for this third aim is that all interventions will be more effective in the following higher risk subgroups: older age; non-HPV related cancer sites; prior surgery; higher radiation dose; chemotherapy (yes); and, prophylactic feeding tube insertion (yes).
Overview of trial design
This is a multi-center, single-blinded 3-arm behavioural intervention pragmatic RCT that will compare the effectiveness of PRO-ACTIVE versus RE-ACTIVE swallowing interventions in patients with HNC receiving RT across eleven sites in Canada and the United States. The PRO-ACTIVE trial design was developed using PRECIS-2 framework for pragmatic trial methodology and adheres to the funding agency, Patient Centered Outcomes Research Institute (PCORI), methodology standards [27, 28]. The research question was determined based on identification of practice variation with clinicians equally committed to each intervention [19, 22], and gap analysis from two recent systematic reviews from the investigative team  and others  establishing clinical equipoise between RE-ACTIVE and PRO-ACTIVE swallowing intervention. Further refinements to the trial protocol, including the selection of secondary outcomes, were made with input from patient and clinical stakeholders following PCORI guidelines for stakeholder engagement. The trial protocol is in accordance with the principles of the Declaration of Helsinki and has been approved by Research Ethics Boards across all sites. The trial was prospectively registered on Clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT03455608). Any changes that need to be made in the trial protocol will be communicated to all investigators, the ethics committees, and the trial registry. Written informed consent will be obtained from each participant.
A total of 952 participants with HNC planned for RT who do not currently have dysphagia will be randomized to receive one of 3 swallowing interventions by speech language pathologists:.
Arm 1. delayed intervention started promptly if/when dysphagia is identified (RE-ACTIVE)
Arm 2. early low intensity intervention started before RT commences (PRO-ACTIVE EAT)
Arm 3. early high intensity intervention started before RT commences (PRO-ACTIVE EAT+ EXERCISE)
The randomization of participants will be stratified by participating site using a centralized, automated and concealed process conducted by the Data Coordinating Center (DCC). Participants and therapy providers will not be blinded; however, clinical raters and data analysts will be blinded to the study arm to minimize bias. Eligible patients will be randomized in a 1:2:2 allocation to RE-ACTIVE (Arm 1, n = 190) and each of the PRO-ACTIVE arms (Arms 2 and 3, n = 381 per group). All patients will be followed to 12 months post-RT. The main intention to treat analysis will compare duration of feeding tube dependence post-RT. The study schemata is shown in Fig. 1.
Cancer treating centers will be included across eleven North American cities to account for possible regional variation (Toronto, Houston, Boston, Madison, New York, London, Montreal, Baltimore, Detroit Miami, Orlando). The Princess Margaret Cancer Centre, part of the University Health Network (PM/UHN) in Toronto, serves as the prime site. In the USA, where patients are as likely to receive treatment at an academic or community facility, we will aim to enroll 50% of participants from both academic and community-based facilities. In Canada, where cancer therapy is regionalized at academic teaching facilities, we will enroll all participants from representative academic centers but across two provinces thereby capturing regional variation.
Eligibility criteria were defined to allow participation of any patient for whom the following decisional dilemma exists: “is there a benefit to proactive swallowing therapy during RT?” In keeping with pragmatic trial standards, the eligibility criteria were operationalized to include any patient who presents to begin RT for HNC with a functional swallow but at high risk for developing post-RT dysphagia: defined as planned RT dose ≥60 Gy with treatment volumes including bilateral neck, based on published prediction models for tube-dependent dysphagia . Our local registries confirm that these criteria should include more than 75% of patients who enter curative (primary or adjuvant) intent RT. As a pragmatic RCT, we will limit restrictiveness of eligibility, thereby seeking to include patients who are commonly excluded from efficacy trials. Specifically, common exclusions we have avoided for this pragmatic study are: prior surgery or RT; non-squamous cell histology; prior swallowing therapies unrelated to current HNC; and selected HNC sites and stages. We will enroll patients with sufficient fluency in written English, French, Spanish or Simplified Chinese to be able to complete the patient reported outcome (PRO) questionnaires and use written therapy materials (i.e., study specific patient hand-outs). Eligibility and retention plans are flexible to avoid exclusion of participants based on co-interventions or complications (e.g., pain management strategies, or prophylactic feeding tube use), thereby supporting our planned subgroup analyses for heterogeneous treatment effects (i.e. Aim 3).
Adults ≥18 years of age diagnosed with head and neck malignancy
RT treatment planned for curative intent
Planned to receive external beam radiotherapy dose ≥60 Gy to bilateral neck volumes at participating institution; and
Sufficient fluency in written English, French, Spanish or Simplified Chinese to be able to complete the study patient reported outcome questionnaires
Distant metastasis at enrollment;
Prior or planned total laryngectomy;
Moderate/severe dysphagia at enrollment per baseline videofluoroscopy DIGEST grade ≥ 2 (as graded per central laboratory review),
Previously seen by speech language pathologist for swallowing therapy for the current head and neck cancer
Diagnosis of second primary non-head and neck cancers in the thorax or the central nervous system at enrollment
Head and neck radiotherapy for thyroid or cutaneous/skin primary tumors, regardless of neck fields.
There will be no purposeful exclusion by age within adult age (18 years of age and older), sex, gender, race, or ethnicity. Instead, the composition of age, women, and minorities will reflect the demographic of subjects with HNC who are treated at participating sites. We will adhere to NIH standards for maintaining and presenting data on self-declared race and ethnicity including two ethnic categories (Hispanic/Latino and Non-Hispanic or Latino) and five racial categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, and White).
At each participating site, coordinators will screen tumour board lists and radiation treatment schedules weekly to identify potentially eligible patients. Site coordinators will then approach the patient at or after their next standard of care clinic appointment (e.g., with radiation oncology, medical oncology, surgery, or speech language pathology) to obtain consent, after a member of the treatment team has first discussed the trial with the patient. All eligible patients who provide informed consent will be consecutively enrolled to capture a representative spectrum of the target population. A screening log will detail clinicopathologic and demographics of all patients screened, approached, enrolled and randomized to examine the representative nature of the trial, and will be transparently reported in accordance with Consolidated Standards of Reporting Trials (CONSORT) standards [30, 31].
Screening before randomization
After giving written informed consent, participants fulfilling all eligibility criteria will be enrolled in the study. Participants will only be randomly assigned to the study intervention after screening for no/mild baseline dysphagia using videofluoroscopic swallow (VFS) study digital recordings. The screening step requires independent and blinded central laboratory review of the baseline VFS by trained speech language pathologists. Baseline dysphagia is operationally defined as a DIGEST  grade of > 2. Screen failure information will be captured in the electronic database to ensure transparent reporting according to the CONSORT guidance. The minimal data set in the screening log includes demography (age, sex, tumor and treatment plan), screen failure details, and eligibility criteria.
Participants are free to withdraw from participation in the study at any time upon request. Furthermore, a site investigator may discontinue or withdraw a participant from the study for the following reasons: if any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant; or, if intent of treatment changes to palliative. The reason for participant discontinuation or withdrawal from the study will be recorded. Subjects who sign the informed consent form and are randomized but do not receive the study intervention may be replaced. Subjects who sign the informed consent form, are randomized and receive the study intervention, but subsequently withdraw or are withdrawn or discontinued from the study, will not be replaced.
This 3-arm pragmatic trial will compare RE-ACTIVE swallow therapy (Arm 1) to two hierarchical conditions of PRO-ACTIVE swallowing therapy (Arms 2 & 3). All arms will receive an identical, routine baseline swallowing evaluation with the speech language pathologist. Before RT begins, patients will be randomized to 1 of 3 conditions of swallowing therapy as detailed below (pre-RT is operationally defined as before RT begins up to RT treatment day 3, to allow baseline procedures to occur on RT day 1, if necessary, when patients return to the cancer center for care):
RE-ACTIVE therapy (arm 1)
Participants will receive no swallowing therapy sessions from the speech language pathologist unless they develop dysphagia. If and when the following signs and symptoms of dysphagia develop, patients will begin RE-ACTIVE therapy as per the same EAT+EXERCISE protocol in Arm 3. The trigger to initiate swallowing intervention was selected based on input from stakeholders including, patients, family members, and a wide array of clinical providers involved in the treatment of HNC patients. Arm 1 participants will “trigger” when any one of the following conditions are met:
Participant reports a common dysphagia symptom (i.e., “choking”) on a standardized PRO screen taken weekly during RT, defined as a score ≥ 6 on the MDASI-HN choke item “difficulty choking on foods or liquids” .
Participant becomes 100% feeding tube dependent as monitored weekly during RT.
Participant develops aspiration pneumonia during RT, as per suspicion by any healthcare team member, that then triggers prescription of an antibiotic.
Participants who develop or endorse any one of the above three trigger conditions will be referred to begin RE-ACTIVE swallowing therapy according to the EAT+EXERCISE model within three RT days of their trigger.
PRO-ACTIVE therapy (arms 2 & 3)
All participants randomized to PRO-ACTIVE arms will receive in person swallowing therapy sessions with a speech language pathologist once before RT begins then every 2 weeks during RT (weeks 2, 4, 6) and coached to continue daily independent therapy in between live sessions. The two PRO-ACTIVE arms will adhere to the same frequency of live sessions but differ in the intensity of the exercise. Specifically,
PRO-ACTIVE “EAT” (Arm 2) will aim to keep the patient eating challenging foods safely and efficiently through the duration of RT (typically 6 to 7 weeks). Arm 2 represents a low intensity PRO-ACTIVE therapy, not requiring any additional exercise or therapy outside of mealtime.
In contrast, PRO-ACTIVE “EAT + EXERCISE” (Arm 3) will include the same therapy as Arm 2 (EAT) and in addition, the patient will be trained in swallowing exercises to be executed independently between meals (EXERCISE). Arm 3 represents a high intensity PRO-ACTIVE therapy asking the patient to perform a standardized set of throat exercises outside of mealtime.
All three swallowing therapy interventions require no training or expertise beyond that of a typical provider, namely a speech language pathologist, in a usual care setting. Each arm represents a reproducible version of therapy options that are currently provided in usual care settings in this population [19, 22]. In keeping with pragmatic trial standards , co-interventions are not prohibited (e.g., pain management, other non-swallowing behavioral therapies, other swallowing therapies post RT, or other systemic cancer treatment including chemotherapy and surgeries), but will be tracked in the trial database. Likewise, patients with feeding tube in situ at baseline will not be excluded, but will be tracked in the trial database. For the purpose of reproducibility and understanding natural adherence, patients will be asked to log adherence to their swallowing therapy interventions with a simple paper “diary” log.
This is a pragmatic RCT. Therefore, effectiveness will be assessed through a series of questionnaires and clinical exams to study swallowing status and swallowing-related QOL. A complete list of study activities is summarized in Table 1. The follow-up schedule is carefully planned to align with the schedule of cancer surveillance visits that patients attend in usual practice setting. We will evaluate patients to 12 months to examine long-term effectiveness. Capture of outcome intervals have been set with wide, but discrete windows to enhance flexibility. In all arms, off schedule visits are allowable should problems arise, as per usual care. Clinical testing specified in the protocol represents what is standard at institutions that have adopted the PRO-ACTIVE models as routine care.
The primary endpoint of duration of feeding tube dependence was selected because of its high relevance and clear importance to both patients and providers [35, 36]. Maintaining the ability to swallow foods and liquids is the primary functional priority ranked by HNC patients both before and after their treatment [35, 37]. Because feeding tube utilization requires greater resource burden, this endpoint is also relevant to administrators and payers who make decisions about whether to support a healthcare service by way of reimbursement, staffing, or endorsement as best practice. Feeding tube dependence is also pragmatic as a primary endpoint because it is universally measured in usual care, that is, providers ask about and document feeding tube status at routine clinical visits. Therefore, our primary endpoint of feeding tube use can be ascertained by medical chart, in clinic, or by our study specific electronic PRO (ePRO) remotely. A participant will be considered lost to follow-up if feeding tube use cannot be ascertained by any means at 12 months post RT.
Secondary outcome measures represent both clinician-graded and patient reported outcome (PROs) measures. These measures were selected based on feasibility  at all sites, psychometric validation, familiarity to the investigative team, and/or wide used in routine settings of care, thereby maintaining pragmatic standards. The secondary outcomes are the following:
The MD Anderson Dysphagia Inventory (MDADI)
MDADI is a widely used PRO instrument to evaluate swallowing-related QOL in HNC patients . The 20-item questionnaire quantifies an individual’s global, physical, emotional, and functional perceptions of swallowing ability. MDADI was internally developed and validated at MD Anderson Cancer Center and has been integrated in the MDACC dysphagia clinic for more than 10 years. Questionnaire development included engagement of providers and patients with HNC who experienced dysphagia iteratively throughout conception and refinement of the final scale. In a validation sample of 100 patients with HNC, concurrent validity was moderate by comparison with the Performance Status Scale-Head and Neck (Spearman correlation, 0.47-0.61). Correlation with the subscales of SF-36 demonstrated convergent and divergent validity of the MDADI. Test-retest reliability (physical, 0.86; emotional, 0.88; functional, 0.88) and internal consistency reliability (overall Cronbach’s alpha, 0.96) were sound . Subsequent validation studies further demonstrated suitable psychometric properties in patients with different ethnic-cultural backgrounds [40,41,42]. Perceived dysphagia as quantified by the MDADI is time-dependent, radiotherapy dose-dependent and varies by extent of surgery and tumor site in HNC samples [35, 43]. The investigators have previously shown a 10-point between-group difference to discriminate a clinically meaningful difference in swallowing outcome .
The MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN)
MDASI-HN is a multi-symptom PRO instrument designed to measure severity or burden of cancer-related symptoms and their interference with or effect on patients’ daily functioning [33, 45]. Symptom burden refers to the severity of physical or mental experience by a patient with a specific symptom. Symptom measures are more specific and direct than QOL measures and thus are more sensitive to treatment-related changes. The 28-item MDASI-HN multi-symptom inventory measures include 13 core items (“systemic symptoms”: pain, fatigue, sleep, etc.), 9 head and neck specific items (“local symptoms”: dry mouth, mucus, shortness of breath, taste, etc.), and 6 interference items (activity, work, relations, etc.). The core MDASI items were validated for use in cancer patient populations regardless of the specific diagnosis or type of therapy  and thus can be used to compare symptom burden between different types of cancer. The 9 head and neck specific items were validated internally at MDACC with regard to construct and concurrent validity in a cohort of 205 HNC patients . Internal consistency reliability is high in the core MDASI score, the 9 head and neck-specific items, and the 6 interference items (Cronbach’s α: 0.72–0.92). MDASI-HN can be completed in less than 7 min. MDASI-HN offers quantification of overall symptom burden, but also 2 dysphagia-specific items (“difficulty swallowing”, “choking”) and will be used to understand and adjust for symptoms such as mouth sores, pain, or dry mouth, that make eating challenging during RT. The investigators have experience in using MDASI-HN in weekly radiation clinics for symptom monitoring with a resultant publication characterizing the evolution and cumulative increase in symptoms weekly during HNC RT . Symptom burden can be considered both a secondary outcome, but also a potential confounder (i.e., competing toxicity) that may influence adherence to swallowing therapy.
Videofluoroscopic Swallow (VFS) Studies
The VFS is a dynamic, radiographic imaging study, in which the patient is administered radiopaque labeled bolus volumes in a series of standardized liquid and solid food consistencies to examine oropharyngeal swallow physiology, aspiration, and/or pharyngeal residue. VFS is considered a gold standard measure of dysphagia in clinical practice and is routinely conducted by speech language pathologists in medical settings. Digital videos from VFS will be scored centrally by a trained speech language pathologist blinded to clinical history using the following measures: DIGEST , pharyngeal constriction ratio (PCR) , penetration-aspiration scale (PAS)  and maximum pharyngoesophageal segment opening (PESmax) . DIGEST, the primary measure to determine study eligibility, was developed and validated by the study team  as a CTCAE compatible VFS-derived severity grade of pharyngeal dysphagia. DIGEST is reliable (intra- and inter-rater weighted k 0.82–0.84 and 0.67–0.81, respectively) and discriminates pharyngeal pathophysiology (MBSImP™©:r = 0.77, p < 0.001), perceived dysphagia (MDADI: r = − 0.41, p < 0.001), and diet (PSS-HN: r = − 0.49, p < 0.001) in HNC survivors . DIGEST is sensitive to change in swallowing function over time . PCR, the primary endpoint of VFS for secondary analysis (Aim 2), is a continuous measure of pharyngeal swallowing strength. PCR is a pixel based measure computing area of the pharynx at maximum constriction at peak swallow over the resting area of the pharynx from the mid-sagittal radiograph. PCR provides a reliable radiographic surrogate measure of pharyngeal strength (measured against gold standard pharyngeal manometry) [47, 51, 52] and discriminates aspiration status in dysphagia populations . PAS is an 8-point ordinal classification of swallow airway safety capturing bolus penetration and aspiration, where a score of 1 indicates no airway entry, 2–5 indicates penetration, and 6–8 indicates aspiration. PAS ratings are highly reliable (ICC for inter- and intra-rater reliability: 0.96 and 0.95–0.97, respectively) and predictive of aspiration pneumonia after chemoradiation (p < 0.001, AUC = 0.72) . PESmax provides a reliable radiographic surrogate marker of stricture at the level of the cricopharyngeal muscle, which if present will critically disrupt transport of the bolus into the esophagus .
Performance Status Scale Head and Neck (PSS-HN)
The PSS-HN  is a 3-item validated semi-structured interview tool capturing normalcy of diet, public eating, and, understandability of speech. Each item is scored from 0 to 100, with the higher score indicating better performance. The PSS-HN correlated well with the FACT-HN, especially for normalcy of diet and eating in public (r = 0.66, p < 0.0001; r = 0.42, p < 0.0001, respectively) and is a reliable tool, sensitive to differences in functioning when applied to HNC patients . The PRO-ACTIVE trial adaptation of PSS-HN includes additional questions regarding tracheotomy status and feeding tube utilization.
Medical Outcome of Dysphagia (MOD)
The Medical Outcomes of Dysphagia (MOD) is a newly developed 3-part inventory that targets patient reported symptoms related to health consequences secondary to dysphagia, namely: malnutrition (MOD-Nutrition), aspiration pneumonia (MOD-Pulmonary) and mood changes such as depression and anxiety (MOD-Psychology) . The MOD-Nutrition sub-scale consists of 13 items, of which all but one have either a 3, 4 or 5-point ordinal response; the remaining item quantifies food intake. The MOD-Pulmonary sub-scale consists of 11 items, of which all have a 5-point ordinal response. Likewise, the MOD-Psychology sub-scale consists of 45 items, of which all have a 5-point ordinal response. The study assessing reliability and divergent validity of the items in the three MOD subscales has recently been completed, and included over 350 patients, among whom 77% had a diagnosis of dysphagia secondary to head and neck cancer. Each of the sub-scales has excellent inter-rater reliability with the following total score ICC (95% confidence interval): MOD-Nutrition, ICC = 0.84 (0.73–0.91); MOD-Pulmonary, ICC = 0.89 (0.81–0.94); and, MOD-Psychology ICC = 0.90 (0.83–0.94). The items on the MOD were derived from an extensive review of the literature combined with collective opinion of clinicians, patients and caregivers .
Cancer Behavior Inventory – Version 3 (CBI-V3)
The Cancer Behavior Inventory was developed as a comprehensive measure of self-efficacy strategies for coping with cancer, drawing from self-regulation and self-efficacy theories [57,58,59]. The most recent version of 27 items has undergone extensive revision to ease administration and strengthen psychometric properties. The measure is designed at a grade 6 reading level and has 7 subscales or factors including Maintaining Activity and Independence, Seeking and Understanding Medical Information, Emotion Regulation, Coping with Treatment Side Effects, Accepting Cancer/Maintaining a Positive Attitude, Seeking Social Support, and Using Spiritual Coping. Internal consistency is reported as Cronbach’s alpha of .946, and test-retest reliability as r = .890 (4 months) with mixed groups of cancer patients . Validity coefficients indicate strong psychometric properties with higher scores on the CBI associated with better adjustment to cancer, higher quality of life, and lower levels of emotional distress. Each item presents an activity a cancer patient might do during and after cancer treatment and is scored on a Likert type scale ranging from 1 (‘not at all confident’) to 7 (‘totally confident’). Scores are derived for each of the subscales as well as an overall total score.
EQ-5D-5L is a modified version of the widely used EuroQOL 5 Dimension . The brief 6-item EQ-5D-5L questionnaire is used to describe and value health. The EQ-5D-5L descriptive system measures five levels of severity in each of the existing five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The questionnaire also contains a Visual Analog Scale, by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).
Intake details, radiation therapy details, systemic therapy/chemotherapy details, tumour status, surgery history, tracheotomy, feeding tube insertion, removal, and use dates, feeding tube dependence, concomitant swallowing therapies, vital status, BMI, and complication details will be collected by review of patient medical record at specified intervals.
All pain medications, including over-the-counter medications, reportedly taken in the past 48 h are noted on the pain medication form in the case record form (CRF) at pre-specified intervals (e.g. baseline, week 6 of RT, 3 months and 12 months post RT).
Interincisal opening will be measured at baseline, and 3 months and 12 months post RT using a standardized TheraBite® Range of Motion Scale (TRMS) . Reference points will be noted (gingiva and/or teeth) on the study case report form.
Hospitalization/ Emergency Department Presentation
Hospitalization and/or emergency department presentation will be abstracted from the medical record and by asking participants to identify such events to any external institutions anytime during their participation in the trial.
Safety and adverse events
The therapy provider and/or study team will review adverse events of special interest (AESI) at each study visit. Two adverse events of special interests (AESIs) in Common Terminology Criteria for Adverse Events, CTCAE version 5  monitored by the DSMB (Data Safety Monitoring Board) for this trial safety include: weight loss of grade > 2, or aspiration of grade > 2. In addition, at week 6 of RT, the study team will record the onset and peak severity of selected adverse events during RT, also graded using CTCAE version 5, for the following categories: dysphagia, oral and pharyngeal mucositis, oropharyngeal pain, nausea, vomiting and dermatitis. Attribution of each AESI to study intervention will be assessed by the clinician and/or study team according to best clinical judgment. It is expected that many of the AESIs will be related to the RT (cancer treatment). The summaries of AESIs will be reviewed regularly by the trial DSMB.
Data management plan
The data management plan was developed in accordance with PCORI Methodology Standards for Data Integrity and Rigorous Analysis. Data sources include the electronic health record, PRO questionnaires, imaging data (videofluoroscopy and DICOM radiation dose-grids), and study specific questionnaires. A robust centralized web-based database was designed and maintained by the Techna Institute: Health Informatics Core, an independent research institute within UHN. Manuals of Procedures (MOP) will ensure harmonized entry of individual data items from each source and site under a common data model structure. Authentication, anonymization, and confidentiality plans are detailed in the contractual arrangement with the Techna Institute.
For the primary endpoint, an intention-to-treat (ITT) approach will be applied incorporating a gate-keeper method to control risk of Type 1 error in the setting of multiple comparisons [64, 65]. The primary hypothesis (Hyp 1.1) is that the combined PRO-ACTIVE interventions (PRO-ACTIVE EAT and PRO-ACTIVE EAT+EXERCISE) will result in a better swallow outcome compared to RE-ACTIVE as measured by duration of feeding tube use in the first year after the completion of RT. If PRO-ACTIVE is superior in Hyp 1.1, we will assess the dose response of the PRO-ACTIVE arms. The secondary hypothesis (Hyp 1.2) is that the most intensive intervention (PRO-ACTIVE EAT+EXERCISE) will be more effective than the least intensive (PRO-ACTIVE EAT).
The initial analysis will compare the RE-ACTIVE group to the combined PRO-ACTIVE groups in terms of the duration of feeding tube use operationalized as count of days of tube use from end of RT to last tube use within the 12-month study period by means of a multiple linear regression model with covariate adjustment. The presence of a feeding tube which is not being used for feeds is disregarded. The treatment effect will be expressed as absolute mean difference along with 95% confidence intervals. If this test yields p < 0.05, the two PRO-ACTIVE groups (EAT versus EAT+EXERCISE) will be compared using the same linear analysis method. The meaningful variables we will include in the regression model are: age (as a continuous variable); HPV status (oropharyngeal site vs all others); surgery (yes/no); chemotherapy (yes/no); radiation dose (as a continuous variable); and, facility (as a categorical variable to account for practice variation across the eleven sites).
The largest threat of missing data is non-random loss of outcomes data for the primary endpoint. Missing data for the primary endpoint is extremely unlikely because it is a simple variable that can be ascertained in clinic or remotely via telephone/web interview of the patient. Non-random missing data is more likely for outcomes requiring clinic examination (i.e., videofluoroscopy) for which we have estimated attrition at 26% based on prior longitudinal work from the investigators . For outcomes missing in > 10% of patients, we will consider multiple approaches. One method we may employ is inverse probability weighting approach to account for statistical uncertainty due to missingness. Another option we will explore is multivariate imputation using chained equations . When similar inferences are derived from complete case analysis and imputation, we will report complete case analysis results for simplicity and transparency.
The analysis of the secondary endpoints is not dependent on the findings of the primary endpoint. The hypothesis (Hyp 2.1) is that the combined PRO-ACTIVE interventions will result in a better secondary outcomes including videofluoroscopic swallowing evaluations, functional status measures, health status measures, and patient reported outcomes 3 months following the completion of RT. For the secondary outcomes, ITT analysis will again use a gate-keeper approach to assess differences between arms. Continuous outcomes will be evaluated with ANCOVA approach (multiple linear models regressing outcome on randomization arm plus the baseline measure for adjustment) at the 3-month post-treatment interval when a baseline measurement is present and a t-test (or suitable replacement) otherwise. The treatment effect will be expressed as the mean adjusted difference, or equivalently, mean adjusted change along with 95% confidence intervals. Binary outcomes will be compared by means of a chi-square test or Fisher’s exact test if expected counts are less than 5 and treatment effects will be expressed as risk differences with 95% confidence intervals. Sensitivity will be assessed in terms of consistency of inference as well as magnitudes of effect size using distributional measures of Minimal Clinically Important Difference (MCID)  or anchor-based MCID  when available to interpret whether observed differences are meaningful. Exploratory analyses will be conducted on all outcomes with repeated measurements using mixed-effect models to examine time by treatment interactions. Exploratory subgroup analyses will examine the relative benefit or harm of the PRO-ACTIVE and RE-ACTIVE swallowing interventions in relevant subgroups according to the following: patient (age, tumor site, prior surgery); and provider (radiation dose, chemotherapy use, prophylactic feeding tube use).
Sub-group analyses (heterogeneous treatment effects, HTEs)
Acknowledging that certain groups may benefit substantially while others may benefit far less, exploratory heterogeneous treatment effect (HTE) analyses are planned (Aim 3). The goal of the HTE analyses is to explore if there are subgroups for whom swallowing interventions have varied impact. For hypothesis-generating analyses, HTEs will be assessed by testing the treatment arm by subgroup interaction. Analyses are planned according to two potential sources of HTE : the patient and provider. For parsimony, a likelihood ratio test will examine proposed HTEs simultaneously. Irrespective of their significance, the subgroup effects will be reported (with 95% confidence intervals) to be assessed in terms of clinical significance.
We have identified several participant subgroups for whom differences in treatment response or swallowing outcomes may exist. Preliminary data suggest superior swallowing outcomes in younger patients , those with HPV-associated cancers [68,69,70] those with no prior surgery , those who receive lower doses of RT , those who avoid chemotherapy [68, 71] and who avoid prophylactic feeding tube placement . Each of these classifications will be examined as relevant subgroups in the exploratory HTE analysis, as justified below:
Sample size calculation
Sample size calculations, based on a 2-sample t-test, assume 952 patients enrolled with 1:4 allocation to RE-ACTIVE (Arm 1, n = 190) and PRO-ACTIVE arms (Arms 2 and 3, n = 381 per group). The attrition factor is set at 5% because the primary endpoint can be ascertained without clinical encounter. Thus, the resultant sample size estimated is 180 in Arm 1, 361 in Arm 2, and 361 in Arm 3. For the primary comparison (Hyp 1.1) of Arm 1 (n = 180) versus the combined Arms 2 and 3 (n = 722), assuming ITT analysis with type 1 error probability of 0.05 (two-sided) yields 80% power to detect a small effect size of .23 SD for duration of feeding tube use. For the analysis of Hyp 1.2 in the gate-keeper approach, we will compare intensity of PRO-ACTIVE therapies (Arm 2 versus Arm 3, n = 361 per group), assuming type 1 error probability of 0.05 (two-sided), we have 80% power to detect again a small effect size of 0.21 SD for the primary endpoint of feeding tube duration. We expect the t-test will not be sufficient as the primary analysis given it does not allow for covariate adjustment. Therefore, we will apply the multiple linear regression model as the primary analysis for Aim 1. The power calculation conducted assuming t-tests for analysis of hypotheses 1.1 and 1.2 and deriving a sample of 952 patients remain sufficient for the linear model because by adjusting for variables associated with the mean response, the distribution of the residuals is expected to improve. Therefore, the power for the same hypothesized difference in the primary outcome attributed to treatment in the regression framework will be at least as much as for that for the t-test.
For the secondary analysis (Aim 2) in the gate-keeper approach, we will compare intensity of PRO-ACTIVE therapies (Arm 2 versus Arm 3, n = 361 per group), assuming type 1 error probability of 0.05 (two-sided), we have 80% power to detect again a small effect size of 0.24 SD for PROs and VFS measures. The attrition factor for the secondary analysis is set at 26% because they are more prone to attrition due to required clinical visits and survey responses required from participants. As an exception, feeding tube dependence at 3-months uses an attrition factor of 5%, for the same rationale as the primary endpoint.
Despite continued improvements in RT techniques to optimize functional outcomes by minimizing collateral normal tissue damage , almost all patients experience some degree of early dysphagia. Dysphagia is not only an acute toxicity but a progressive and chronic issue particularly relevant to the rapidly growing pool of younger HNC survivors who achieve long-term cure .
Several single institution observational and controlled efficacy trials as well as two recent systematic reviews have shown benefits of swallowing therapy, regardless of its timing and intensity, to various outcomes, including feeding tube dependence, QOL, swallow efficiency, function, and swallow physiology [21, 23]. While offering a strong evidence base for efficacy of swallowing interventions in this population, these small efficacy trials and meta-analyses were unable to identify the timing (PRO-ACTIVE versus RE-ACTIVE) or intensity (less versus more) that is most effective in treating dysphagia. As such, the PRO-ACTIVE trial was designed as a pragmatic, real-world examination to compare effectiveness of 3 models of swallowing therapy during the radiotherapy interval.
Strengths and limitations
Stakeholder engagement in the development and implementation of the PRO-ACTIVE trial is a major strength. In keeping with the PCORI standards, stakeholder consultation and collaboration was built into all study phases, from conception through dissemination. As an initial step in engagement, the trial concept was presented to the National Foundation on Swallowing Disorders (NFOSD) who endorsed the relevance of the decisional dilemma. Provider stakeholders in the investigators’ Radiation-Associated Dysphagia Investigative Working Group also met over 30 h to refine proposed Arms, pragmatically align methodologic decisions, and to enhance feasibility of study procedures across different geographic and sociodemographic settings. Stakeholder panels in both Canada and the USA share governance and consultation over the life of the study. Diverse stakeholders representing the perspectives of patients, caregivers, physicians, allied health care providers, policy makers, and payors convene in these panels at regular intervals to advise the investigators in key trial issues. Stakeholder engagement has informed operationalization of the ‘trigger’ criteria for the RE-ACTIVE therapy arm, secondary outcome measurement, recruitment/retention strategies, and the content of study-specific patient educational materials.
PRO-ACTIVE was designed in accordance with pragmatic trial standards. The investigators used the PRECIS-2 tool [27, 28] to guide development of the trial protocol to ensure that findings are derived from a study design that is reflective of, and thus generalizable to, the real-world setting. For this reason, outcome measures represent those most practically implemented in the clinical setting. A limitation of the trial protocol includes the omission of detailed RT dose data, specifically including the dose distributions to normal tissues (commonly referred to as organs-at-risk, or OARs). While it is outside the scope of the PRO-ACTIVE trial protocol to analyze RT plans to extract OAR dose, the trial protocol includes the upload and archiving of the full RT DICOM data set including the anatomic imaging and dose files. This RT plan archive will allow the investigators the opportunity for future post-hoc correlative analysis of RT plans with other trial data.
Other key omissions from the trial protocol include details of financial burden or cost incurred by patients and their caregivers. The investigators recognize the critical importance of this issue in modern healthcare. This domain was outside the scope of allowable funding for the PRO-ACTIVE trial. The investigators intend to consider alternate funding sources to examine cost in a subset of PRO-ACTIVE trial participants for exploratory or hypothesis-generating purposes. Another avenue for future or related work is qualitatively exploring the perspective of patients, caregivers, and providers in the lived experience of swallowing therapy during the PRO-ACTIVE study.
The data obtained from PRO-ACTIVE is intended to help address the decisional dilemma about which type and timing of swallowing therapy provides the best outcomes in the real world and in distinct subgroups of HNC survivors. Given the minimal risk associated with participation, there is great potential benefit from this study to improve quality of care and QOL in HNC survivorship. Also, since all participants enrolled in PRO-ACTIVE will receive a form of swallowing therapy, there is potential for individual benefit in all arms. There is currently insufficient evidence to guide decisions of best swallowing therapy options in real world settings. Once clinically manifested, radiation-associated dysphagia is difficult to reverse. Real world comparisons of common therapies represent a critical step forward to improve quality of care in the health care system and the QOL of individual patients. These data might also translate to better health by way of improved nutritional status and diminished risk of death from aspiration pneumonia. The potential yield is far greater than the minimal risk imposed upon patients enrolled to the trial.
Availability of data and materials
Adverse Events of Special Interest
Analysis of Covariance
Consolidated Standards of Reporting Trials
Case Report Form
Data Coordinating Center
Data Safety Monitoring Board
Electronic Case Report Forms
Head and Neck Cancer
Institutional Review Board
Minimal Clinically Important Difference
MD Anderson Cancer Center
Manual of Procedures
National Clinical Trial
- NIH :
National Institutes of Health
Princess Margaret Cancer Centre
Patient Reported Outcomes
Quality of Life
Research Ethics Board
Schedule of Activities
University Health Network
Videofluoroscopic assessment of swallow
Xu B, Boero IJ, Hwang L, Le QT, Moiseenko V, Sanghvi PR, et al. Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer. Cancer. 2015;121(8):1303–11. https://doi.org/10.1002/cncr.29207.
Hunter KU, Lee OE, Lyden TH, Haxer MJ, Feng FY, Schipper M, et al. Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors. Head Neck. 2014;36(1):120–5. https://doi.org/10.1002/hed.23275.
Hutcheson KA, Bhayani MK, Beadle BM, Gold KA, Shinn EH, Lai SY, et al. Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it. JAMA Otolaryngol Head Neck Surg. 2013;139(11):1127–34. https://doi.org/10.1001/jamaoto.2013.4715.
Setton J, Lee NY, Riaz N, Huang SH, Waldron J, O'Sullivan B, et al. A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. Cancer. 2015;121(2):294–301. https://doi.org/10.1002/cncr.29022.
Mortensen HR, Jensen K, Aksglaede K, Lambertsen K, Eriksen E, Grau C. Prophylactic swallowing exercises in head and neck cancer radiotherapy. Dysphagia. 2015;30(3):304–14. https://doi.org/10.1007/s00455-015-9600-y.
Ohba S, Yokoyama J, Kojima M, Fujimaki M, Anzai T, Komatsu H, et al. Significant preservation of swallowing function in chemoradiotherapy for advanced head and neck cancer by prophylactic swallowing exercise. Head Neck. 2016;38(4):517–21. https://doi.org/10.1002/hed.23913.
van der Molen L, van Rossum MA, Rasch CR, Smeele LE, Hilgers FJ. Two-year results of a prospective preventive swallowing rehabilitation trial in patients treated with chemoradiation for advanced head and neck cancer. Eur Arch Otorhinolaryngol. 2014;271(5):1257–70. https://doi.org/10.1007/s00405-013-2640-8.
Carroll WR, Locher JL, Canon CL, Bohannon IA, McColloch NL, Magnuson JS. Pretreatment swallowing exercises improve swallow function after chemoradiation. Laryngoscope. 2008;118(1):39–43. https://doi.org/10.1097/MLG.0b013e31815659b0.
Shaw SM, Flowers H, O'Sullivan B, Hope A, Liu LW, Martino R. The effect of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement on swallowing and swallow-related outcomes in patients undergoing radiotherapy for head and neck cancer: a systematic review. Dysphagia. 2015;30(2):152–75. https://doi.org/10.1007/s00455-014-9592-z.
MD Anderson Head and Neck Cancer Symptom Working Group. Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiother Oncol. 2016;118(2):304–14. https://doi.org/10.1016/j.radonc.2016.01.019.
Eisbruch A, Kim HM, Feng FY, Lyden TH, Haxer MJ, Feng M, et al. Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys. 2011;81(3):E93–E9. https://doi.org/10.1016/j.ijrobp.2010.12.067.
Hutcheson KA, Lewin JS, Barringer DA, Lisec A, Gunn GB, Moore MW, et al. Late dysphagia after radiotherapy-based treatment of head and neck cancer. Cancer. 2012;118(23):5793–9. https://doi.org/10.1002/cncr.27631.
Rubin EB, Buehler AE, Halpern SD. States worse than death among hospitalized patients with serious illnesses. JAMA Intern Med. 2016;176(10):1557–9. https://doi.org/10.1001/jamainternmed.2016.4362.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.
Statistics. CCSsACoC. Canadian Cancer Statistics 2016. Toronto, ON; 2016.
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294–301. https://doi.org/10.1200/JCO.2011.36.4596.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35. https://doi.org/10.1056/NEJMoa0912217.
Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clinic Oncol. 2006;24(5):736–47. https://doi.org/10.1200/JCO.2004.00.3335.
Krisciunas GP, Sokoloff W, Stepas K, Langmore SE. Survey of usual practice: dysphagia therapy in head and neck cancer patients. Dysphagia. 2012;27(4):538–49. https://doi.org/10.1007/s00455-012-9404-2.
Hutcheson KA, Gomes A, Rodriguez V, Barringer D, Khan M, Martino R. Eat all through radiation therapy (EAT-RT): structured therapy model to facilitate continued oral intake through head and neck radiotherapy-user acceptance and content validation. Head Neck. 2020;42(9):2390–6. https://doi.org/10.1002/hed.26250.
Greco E, Simic T, Ringash J, Tomlinson G, Inamoto Y, Martino R. Dysphagia treatment for patients with head and neck Cancer undergoing radiation therapy: a Meta-analysis review. Int J Radiat Oncol Biol Phys. 2018;101(2):421–44. https://doi.org/10.1016/j.ijrobp.2018.01.097.
Roe JW, Carding PN, Rhys-Evans PH, Newbold KL, Harrington KJ, Nutting CM. Assessment and management of dysphagia in patients with head and neck cancer who receive radiotherapy in the United Kingdom - a web-based survey. Oral Oncol. 2012;48(4):343–8. https://doi.org/10.1016/j.oraloncology.2011.11.003.
Perry A, Lee SH, Cotton S, Kennedy C. Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers. Cochrane Database Syst Rev. 2016;8:CD011112. https://doi.org/10.1002/14651858.CD011112.pub2.
Beadle BM, Liao KP, Giordano SH, Garden AS, Hutcheson KA, Lai SY, et al. Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: a surveillance, epidemiology, and end results-Medicare analysis. Cancer. 2017;123(2):283–93. https://doi.org/10.1002/cncr.30350.
McEwen S, Rodriguez AM, Martino R, Poon I, Dunphy C, Rios JN, et al. "I didn't actually know there was such a thing as rehab": survivor, family, and clinician perceptions of rehabilitation following treatment for head and neck cancer. Support Care Cancer. 2016;24(4):1449–53. https://doi.org/10.1007/s00520-015-3021-1.
Nund RL, Ward EC, Scarinci NA, Cartmill B, Kuipers P, Porceddu SV. Carers' experiences of dysphagia in people treated for head and neck cancer: a qualitative study. Dysphagia. 2014;29(4):450–8. https://doi.org/10.1007/s00455-014-9527-8.
Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350(may08 1):h2147. https://doi.org/10.1136/bmj.h2147.
Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62(5):464–75. https://doi.org/10.1016/j.jclinepi.2008.12.011.
Wopken K, Bijl HP, van der Schaaf A, Christianen ME, Chouvalova O, Oosting SF, et al. Development and validation of a prediction model for tube feeding dependence after curative (chemo-) radiation in head and neck cancer. PLoS One. 2014;9(4):e94879. https://doi.org/10.1371/journal.pone.0094879.
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10(1):28–55. https://doi.org/10.1016/j.ijsu.2011.10.001.
Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2011;9(8):672–7. https://doi.org/10.1016/j.ijsu.2011.09.004.
Hutcheson KA, Barrow MP, Barringer DA, Knott JK, Lin HY, Weber RS, et al. Dynamic imaging grade of swallowing toxicity (DIGEST): scale development and validation. Cancer. 2017;123(1):62–70. https://doi.org/10.1002/cncr.30283.
Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007;29(10):923–31. https://doi.org/10.1002/hed.20602.
Segal J, Weiss C, Varadhan R. Understanding heterogeneity of treatment effects in pragmatic trials with an example of a large, simple trial of a drug treatment for osteoporosis (white paper). Center for Medical Technology and Policy; 2012.
Wilson JA, Carding PN, Patterson JM. Dysphagia after nonsurgical head and neck cancer treatment: Patients' perspectives. Otolaryng Head Neck. 2011;145(5):767–71. https://doi.org/10.1177/0194599811414506.
Owadally W, Hurt C, Timmins H, Parsons E, Townsend S, Patterson J, et al. PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV) positive oropharyngeal cancer. BMC Cancer. 2015;15(1):602. https://doi.org/10.1186/s12885-015-1598-x.
List MA, Mumby P, Haraf D, Siston A, Mick R, MacCracken E, et al. Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer. Qual Life Res. 1997;6(3):274–84. https://doi.org/10.1023/a:1026419023481.
Martino R, Ringash J, Durkin L, Greco E, Huang SH, Xu W, et al. Feasibility of assessing patient health benefits and incurred costs resulting from early dysphagia intervention during and immediately after chemoradiotherapy for head-and-neck cancer. Curr Oncol. 2017;24(6):e466–e76. https://doi.org/10.3747/co.24.3543.
Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M.D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg. 2001;127(7):870–6.
Carlsson S, Ryden A, Rudberg I, Bove M, Bergquist H, Finizia C. Validation of the Swedish M. D. Anderson dysphagia inventory (MDADI) in patients with head and neck cancer and neurologic swallowing disturbances. Dysphagia. 2012;27(3):361–9. https://doi.org/10.1007/s00455-011-9375-8.
Schindler A, Borghi E, Tiddia C, Ginocchio D, Felisati G, Ottaviani F. Adaptation and validation of the Italian MD Anderson dysphagia inventory (MDADI). Revue de laryngologie - otologie - rhinologie. 2008;129(2):97–100.
Kwon CH, Kim YH, Park JH, Oh BM, Han TR. Validity and reliability of the korean version of the MD Anderson dysphagia inventory for head and neck cancer patients. Ann Rehabil Med. 2013;37(4):479–87. https://doi.org/10.5535/arm.2013.37.4.479.
Dwivedi RC, Chisholm EJ, Khan AS, Harris NJ, Bhide SA, St Rose S, et al. An exploratory study of the influence of clinico-demographic variables on swallowing and swallowing-related quality of life in a cohort of oral and oropharyngeal cancer patients treated with primary surgery. Eur Arch Otorhinolaryngol. 2012;269(4):1233–9. https://doi.org/10.1007/s00405-011-1756-y.
Hutcheson KA, Barrow MP, Lisec A, Barringer DA, Gries K, Lewin JS. What is a clinically relevant difference in MDADI scores between groups of head and neck cancer patients? Laryngoscope. 2016;126(5):1108–13. https://doi.org/10.1002/lary.25778.
Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients - the MD Anderson Symptom Inventory. Cancer. 2000;89(7):1634–46. https://doi.org/10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V.
Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, et al. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer. Cancer. 2014;120(13):1975–84. https://doi.org/10.1002/cncr.28672.
Leonard R, Rees CJ, Belafsky P, Allen J. Fluoroscopic surrogate for pharyngeal strength: the pharyngeal constriction ratio (PCR). Dysphagia. 2011;26(1):13–7. https://doi.org/10.1007/s00455-009-9258-4.
Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetration-aspiration scale. Dysphagia. 1996;11(2):93–8. https://doi.org/10.1007/BF00417897.
Leonard R, Kendall K. Dysphagia assessment and treatment planning : a team approach. Fourth edition. ed. San Diego: Plural Publishing; 2019. xiv, 388 pages p.
Hutcheson KA, Warneke CL, Yao C, Zaveri J, Elgohari BE, Goepfert R, et al. Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2019;145(11):1053–63.
Lan Y, Xu G, Dou Z, Lin T, Yu F, Jiang L. The correlation between manometric and videofluoroscopic measurements of the swallowing function in brainstem stroke patients with dysphagia. J Clin Gastroenterol. 2015;49(1):24–30. https://doi.org/10.1097/MCG.0000000000000100.
Leonard R, Belafsky PC, Rees CJ. Relationship between fluoroscopic and manometric measures of pharyngeal constriction: the pharyngeal constriction ratio. Ann Otol Rhinol Laryngol. 2006;115(12):897–901. https://doi.org/10.1177/000348940611501207.
Leonard R. Predicting aspiration risk in patients with dysphagia: evidence from fluoroscopy. Laryngoscope Investig Otolaryngol. 2019;4(1):83–8. https://doi.org/10.1002/lio2.226.
List MA, Rittersterr C, Lansky SB. A performance status scale for head and neck-cancer patients. Cancer. 1990;66(3):564–9. https://doi.org/10.1002/1097-0142(19900801)66:3<564::AID-CNCR2820660326>3.0.CO;2-D.
List MA, D'Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, et al. The performance status scale for head and neck Cancer patients and the functional assessment of Cancer therapy-head and neck scale. A study of utility and validity. Cancer. 1996;77(11):2294–301. https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2294::AID-CNCR17>3.0.CO;2-S.
Martino R, Beaton D, Diamant NE. Using different perspectives to generate items for a new scale measuring medical outcomes of dysphagia (MOD). J Clin Epidemiol. 2009;62(5):518–26. https://doi.org/10.1016/j.jclinepi.2008.05.007.
Heitzmann CAMT, Jean-Pierre P, Roscoe JA, Kirsh KL, Passik SD. Assessing self-efficacy for coping with cancer: development and psycometric analysis of the brief version of Cancer behavior inventory (CBI-B). Psycho-oncology. 2011;20(3):302–12. https://doi.org/10.1002/pon.1735.
Merluzzi TVMSM. Assessment of self-efficacy and coping with cancer: development and validation of the Cancer and behaviour inventory. Health Psychol. 1997;16(2):163–70. https://doi.org/10.1037/0278-6126.96.36.199.
Mertuzzi TVNR, Hedge K, Martinez Sanchez MA, Dunn L. Self-efficacy for coping with cancer: revision of the Cancer behavior inventory (version 2.0). Psycho-oncology. 2001;10(3):206–17. https://doi.org/10.1002/pon.511.
Merluzzi TVPE, Heitzmann Ruhf CA, Liu H, Yang M, Conley CC. Self-efficacy for coping with cancer: revision of the Cancer behavior inventory (version 3.0). Psychological Assessment. 2017.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.
Saund DS, Pearson D, Dietrich T. Reliability and validity of self-assessment of mouth opening: a validation study. BMC Oral Health. 2012;12(1):48. https://doi.org/10.1186/1472-6831-12-48.
(CTEP) CTEP. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 USA: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES; 2017 [Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
Dmitrienko A, Offen WW, Westfall PH. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Stat Med. 2003;22(15):2387–400. https://doi.org/10.1002/sim.1526.
Wang R, Ware JH. Detecting moderator effects using subgroup analyses. Prev Sci. 2013;14(2):111–20. https://doi.org/10.1007/s11121-011-0221-x.
Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res. 2011;20(1):40–9. https://doi.org/10.1002/mpr.329.
Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a standard deviation: confirmation through another look. Expert Rev Pharmacoecon Outcomes Res. 2004;4(5):581–5. https://doi.org/10.1586/14737188.8.131.521.
Denaro N, Merlano MC, Russi EG. Dysphagia in head and neck cancer patients: pretreatment evaluation, predictive factors, and assessment during radio-chemotherapy, recommendations. Clin Exp Otorhinolaryngol. 2013;6(3):117–26. https://doi.org/10.3342/ceo.2013.6.3.117.
Naik M, Ward MC, Bledsoe TJ, Kumar AM, Rybicki LA, Saxton JP, et al. It is not just IMRT: human papillomavirus related oropharynx squamous cell carcinoma is associated with better swallowing outcomes after definitive chemoradiotherapy. Oral Oncol. 2015;51(8):800–4. https://doi.org/10.1016/j.oraloncology.2015.04.008.
Starmer HM, Tippett D, Webster K, Quon H, Jones B, Hardy S, et al. Swallowing outcomes in patients with oropharyngeal cancer undergoing organ-preservation treatment. Head Neck. 2014;36(10):1392–7. https://doi.org/10.1002/hed.23465.
Wall LR, Ward EC, Cartmill B, Hill AJ, Porceddu SV. Adherence to a prophylactic swallowing therapy program during (chemo) radiotherapy: impact of service-delivery model and patient factors. Dysphagia. 2016;32(2):279–92. https://doi.org/10.1007/s00455-016-9757-z.
The authors acknowledge Lisa Durkin, Denise Barringer, all PRO-ACTIVE Stakeholders, and the entire PRO-ACTIVE study team of investigators, staff and clinicians for their invaluable feedback to the various iterations of the study design.
Third party submissions – not applicable.
Overview of Overall Study Coordination and Data Monitoring Committee.
The Applied Health Research Centre (‘AHRC’) of St. Michael’s Hospital in Toronto, Ontario is an academic research organization (ARO) affiliated with the University of Toronto and will serve as the primary trial coordinating site. AHRC is responsible for project management and monitoring, including yearly audit of trial conduct across all sites under the oversight of the sponsor investigator. The AHRC Project Manager will be the primary contact for the trial for all matters related to trial conduct and regulatory oversight.
The Data Safety and Monitoring Board (DSMB), coordinated by AHRC, is an independent group, appointed by and advisory to the Executive Committee (EC) of the PROACTIVE study and will remain standing until the end of trial accrual. All DSMB members are expected to remain free from perceived or actual conflict of interest throughout their involvement in the trial, and will be asked to complete a conflict of interest form at the start of their involvement in the DSMB. The DSMB is responsible for safeguarding the interests of study participants, and assessing the safety of study procedures, and is required to provide recommendations about continuing or stopping the study, based on safety considerations. DSMB procedures will follow methods in accordance with PCORI standards.
The governance structure of the PROACTIVE trial will be led by an executive committee (EC), composed of the two Co-PIs, RM and KH, as well as Co-Investigators KET, CLM, JR, TMcC, and DFC. Representatives on the EC include both PIs, and investigators representing Radiation Oncology, Surgery, Statistics, and Engagement. The EC will manage the long-term milestones and research directions, as well as the overall engagement with the stakeholders. The EC will have a full (virtual) meeting on a quarterly basis, as well as shorter monthly meetings focused on enrollment, project milestones, and specific issues that arise. Quarterly meetings will include review and action on the engagement top-line reports.
Patient-Centered Outcomes Research Institute (PCORI), a United States-based non-governmental institute, has funded this project. PCORI has no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Ethics approval and consent to participate
All versions of the study protocol and informed consent forms will be reviewed and approved by the Research Ethics Board (REB/Institutional Review Board (IRB) of each site before the trial is implemented. The Princess Margaret Cancer Centre (PM), part of the University Health Network (UHN) in Toronto, ON is the prime site and was reviewed by Clinical Trials Ontario, as the review of record (CTO Project ID: 1363). In addition, the remaining ten participating sites also underwent local ethics review. Across all sites, PRO-ACTIVE informed consent forms are harmonized for relevant trial particulars while adhering to local REB/IRB standards. As part of the informed consent process, the PRO-ACTIVE study team will only approach participants once they have shown interest in the trial to a member from their direct circle of care. The study team will explain the research study to the participant and answer any questions that may arise. A verbal explanation will be provided in terms suited to the participant’s comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Participants will have the opportunity to carefully review the written consent form, ask questions and discuss the study with their family or surrogates prior to agreeing to participate. The participant will sign the informed consent document prior to any procedures being done specifically for the study. Participants will be informed that participation is voluntary and that they may withdraw from the study at any time, without prejudice. A copy of the informed consent document will be given to the participants for their records. The informed consent process will be conducted and documented in the source document (including the date), and the form signed, before the participant undergoes any study-specific procedures. The rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Martino, R., Fitch, M.I., Fuller, C.D. et al. The PRO-ACTIVE trial protocol: a randomized study comparing the effectiveness of PROphylACTic swallow InterVEntion for patients receiving radiotherapy for head and neck cancer. BMC Cancer 21, 1100 (2021). https://doi.org/10.1186/s12885-021-08826-0
- Head and neck cancer survivors
- Feeding tube duration